Avidity Biosciences
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-01-01
- Employees
- 253
- Market Cap
- $5.1B
- Introduction
Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.
Avidity Biosciences, Inc. (RNA) Stock Price, News, Quote & Insights
Avidity Biosciences, Inc. (RNA) specializes in RNA therapeutics, focusing on rare diseases with its AOC products. Currently, AOC 1001 for myotonic dystrophy type 1 is in phase 1/2 trials. The company, based in San Diego, has a market cap of $3.6B and faces financial challenges with a negative EPS of -2.88.
Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization
Avidity Biosciences plans a Biologics License Application (BLA) for del-zota by end of 2025, with accelerated approval confirmed. It aims to complete Phase 3 trials for del-desiran and del-brax, and expand leadership for global commercialization. The company focuses on RNA therapeutics for rare diseases, with key presentations and trials scheduled throughout 2025.
Neumirna Therapeutics Raises €20M in Series A Funding
Neumirna Therapeutics raised €20M in Series A funding led by Angelini Ventures and Invivo Partners. The funds will support clinical development of NMT.001 for drug-resistant epilepsy, expand R&D, and scale its RNA-based drug discovery platform targeting intractable conditions like epilepsy and Parkinson’s disease.
Avidity Biosciences Announces Inducement Grants Under 2022 Inducement Plan
Avidity Biosciences granted Charles Calderaro III 80,000 stock options and 40,000 RSUs as part of his hiring as Chief Technical Officer, under the 2022 Inducement Plan. The awards vest over four years, contingent on continued employment. Avidity focuses on RNA therapeutics, specifically AOCs™, targeting rare diseases and advancing in cardiology and immunology.
Avidity Biosciences Accelerates Path to First Drug Approval, Expands Leadership for 2025
Avidity Biosciences plans a Biologics License Application (BLA) for del-zota by end of 2025, targeting DMD44. It aims to complete Phase 3 trials for del-desiran and del-brax, with potential global commercialization. Leadership expands to support growth, focusing on rare diseases and precision cardiology.
Avidity Biosciences Plans First BLA Submission for Del-Zota by End-2025
Avidity Biosciences plans a Biologics License Application (BLA) for del-zota by end-2025, targeting DMD44. It aims to complete Phase 3 trials for del-desiran and del-brax, with potential global commercialization. Leadership expands to support growth, focusing on rare diseases and precision cardiology.
Avidity Biosciences, Inc. (RNA) Latest Stock News & Transformative Plans for 2025
Avidity Biosciences plans a transformative 2025, aiming for a BLA submission for delpacibart zotadirsen and advancing three rare muscle disease programs. It's expanding into precision cardiology, targeting genetic cardiomyopathies, and pursuing accelerated approval for delpacibart braxlosiran in FSHD treatment.
A Look Back at Major Announcements in 2024
2024 marked a pivotal year for Google AI, with major updates like Circle to Search, Gemini 2.0 models, and AI-powered features across products. Key announcements included AI advancements in health, education, and sustainability, alongside significant partnerships and investments in AI infrastructure and skills development.
Seven Biopharma Trends to Watch in 2025
75% of C-suite executives in life sciences are optimistic about 2025, citing growth and innovation. AI in biopharma is expanding, with increased investments and partnerships. Cancer vaccines and gene editing are advancing, with late-stage trials and new therapies. VC and IPO markets are rebounding, and M&A activity is expected to increase. Multiomics tools are expanding, and spatial biology is consolidating. Regulatory changes under Trump 2.0 may impact biopharma and health policy.
Related Clinical Trials:
Novel test can detect different types of asthma via nasal swab
A novel nasal swab test developed by University of Pittsburgh researchers can differentiate asthma subtypes by analyzing RNA, aiming to improve personalized treatment, especially for Black and Puerto Rican children who face higher asthma rates. Published in JAMA, the test identifies specific genetic markers for inflammation, offering a more precise diagnosis than current methods.
© Copyright 2025. All Rights Reserved by MedPath